Press Releases

Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships.

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster SALT LAKE CITY , TORONTO and MONTRÉAL , July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize

TORONTO , June 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its 28,000 square foot Toronto site, which will serve as the headquarters for Recursion Canada.

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.

SALT LAKE CITY , June 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Goldman Sachs 44th Annual Global Healthcare Conference – June

Altitude’s new facility will be housed within Recursion’s expanded headquarters and will promote increased collaboration in Downtown Salt Lake City’s rapidly growing biotech innovation ecosystem. SALT LAKE CITY , May 25, 2023 (GLOBE NEWSWIRE) -- Altitude Lab announced today that its incubator

SALT LAKE CITY , May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro , M.D., Ph.D, as its Chief Medical Officer. Dr.

Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological targets Advanced 4 active clinical trials, including an exploratory Phase 2 study of REC-994 in

SALT LAKE CITY and TORONTO and MONTRÉAL , May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space:

Salt Lake City , May 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities 2023 Health Care